April 12th 2024
Data showed that 87.8% of treated patients and 96.1% of patients who completed the study achieved normal 24-hour mean plasma testosterone values (222 to 800 ng/dL) at 90-day follow-up.
September 28th 2023
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
How the economy predicts PCa diagnosis, management
February 1st 2016Researchers hypothesized that during a time of resource scarcity, the incidence of PSA-detected prostate cancer would decrease and the use of noncurative management strategies would increase, reports Urology Times SUO internship program member Ryan Hutchinson, MD.
Prognostic factors identified in patients taking PCa Tx
February 1st 2016Analyses of overall survival rates among subgroups of men who received radium-223 dichloride (Ra 223; Xofigo) as part of an expanded access program suggest factors that may have prognostic significance, including effects of prior and concomitant treatments.
Study: mpMRI predicts lymph node involvement
January 1st 2016A combination of findings on preoperative multi-parametric magnetic resonance imaging showed good accuracy for predicting lymph node involvement on final pathology in men who underwent robot-assisted radical prostatectomy for prostate cancer, reported researchers from the National Institutes of Health, Bethesda, MD.
Uro Pipeline: 1st patients treated in phase III study of investigational BPH Tx
January 1st 2016Other pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.
Evaluating web videos found feasible for RARP peer review
January 1st 2016Evaluation of online videos is a feasible method for peer review of robot-assisted radical prostatectomy surgical skills, according to a pilot project undertaken by the Michigan Urological Surgery Improvement Collaborative (MUSIC).
Survey reveals why patients discontinue IPP use
January 1st 2016Ten percent of men with penile implants express dissatisfaction with their implant, and 12% either do not use their implant or use it less often than desired, according to data from a patient registry known as PROPPER (Prospective Registry of Outcomes with Penile Prostheses for Erectile Restoration).
AUA Peyronie’s guideline: Dr. Burnett offers highlights
November 23rd 2015The recently published AUA practice guideline on Peyronie’s disease provides current clinical principles on diagnosis and treatment of a highly prevalent and clinically significant condition, according to the co-chair of the multidisciplinary panel that developed the guideline.